Navigation Links
Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
Date:3/1/2012

Cambridge, Mass., and Worcester, Mass., March 1, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I '726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the '726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.

Inventors on the patent are David P. Bartel, PhD, a Howard Hughes Medical Institute Investigator and professor of biology at the Massachusetts Institute of Technology; Phillip A. Sharp, PhD, Institute Professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a 1993 Nobel Laureate; Thomas Tuschl, PhD, a Howard Hughes Medical Institute Investigator and professor at Rockefeller University; and Phillip D. Zamore, PhD, a Howard Hughes Medical Institute Investigator and the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, where he co-directs the RNA Therapeutics Institute.

"The Tuschl family of patents defines key discoveries central to the advancement of RNAi therapeutics to patients," said James P. McNamara, PhD, executive director, Office of Technology Management, University of Massachusetts Medical School. "The Tuschl I patent is a critical invention by Professors Tuschl, Zamore, Bartel, and Sharp regarding the RNAi mechanism. We are pleased to see this patent fully upheld in Europe in these opposition proceedings."

"We are very pleased with the outcome of these opposition proceedings which resulted in the claims from the Tuschl I '726 patent being fully upheld. This decision by the EPO affirms our belief in the validity of these claims, and the novelty of the Tuschl I invention, and supports the relevance of Tuschl
'/>"/>

Contact: Mark Shelton
mark.shelton@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
2. UMass Medical School study points to genetic link in apnea of prematurity
3. UMASS Medical Schools human stem cell bank makes available first seven stem cell lines
4. UMass Amherst biologists use GPS to map bats teeth to explore evolutionary adaptations to diet
5. UMass med school professor wins coveted emerging-investigator award
6. UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts
7. UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate
8. UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center
9. UMass Amherst ecologists among the first to record and study deep-sea fish noises
10. Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material
11. UMass Amherst chemical engineers say mini-cellulose molecule unlocks biofuel chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... have been selected for awards from the Merck/AAAS ... Institute for Science Education (MISE) and the American ... program awards provide up to $60,000, paid over ... chemistry departments at the recipient institution. This ...
... SALT LAKE CITYUnraveling the genetics of social behavior and ... the Salk Institute for Biological Studies have traced the ... genetic disorder known as Williams Syndrome. Their ... of the American Journal of Medical Genetics , ...
... The genome of the evolutionary ancestor of humans and present-day ... DNA, according to a study to be published in ... birthday. "The new study shows big differences in ... containing rapidly evolving genes. Most of these differences occurred at ...
Cached Biology News:2 genes influence social behavior, visual-spatial performance in people with Williams syndrome 22 genes influence social behavior, visual-spatial performance in people with Williams syndrome 3Ancestral genome of present-day African great apes & humans had burst of DNA sequence duplication 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 “Science can be ... and fifth-graders participated in an “Introduce a Girl to Engineering ... February. Lessons in light-based science and technology were presented by ... Student Chapters awarded a total of $60,000 in International ... international society for optics and photonics . The IYL grants ...
(Date:4/1/2015)... SEATTLE , April 1, 2015  Adaptive ... The Lancet Oncology showing ... the company,s next-generation sequencing-based minimal residual disease (MRD) ... clonoSEQ™ MRD test) accurately identifies patients with diffuse ... of relapse after initial treatment, usually several months ...
(Date:4/1/2015)... City, UT (PRWEB) April 01, 2015 ... agreement allowing Biosearch to make, use, market and ... agreement also licenses CoPrimers™ technology to Biosearch for ... patent-pending design greatly reduces the occurrence of primer-dimers, ... resulting in increased sensitivity and lower test prices. ...
(Date:4/1/2015)... Shimadzu Corporation announced that its ... system (Nexera UC) received the Pittcon Editors’ Gold ... Chemistry and Applied Spectroscopy (Pittcon) held in New ... , The Pittcon Editors’ Awards recognize the most ... time based on votes by the media corps. ...
Breaking Biology Technology:Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 2Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 2Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 3Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2
... ... ... 27, 2009 -- Global food security, which is increasingly being recognized as a key ... private partnerships, William S. Niebur , vice president – DuPont Crop Genetics Research ...
... Organovo, Inc., a regenerative medicine company focused on bioprinting ... M.B.A, to its board of directors. Baltera is the ... and has over 19 years of pharmaceutical and biotechnology ... of the life sciences industry will provide great value ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA ), ... that,it has received its third purchase order for its ... Technology for the national,stockpiling plan. Under this purchase order, ... of PANFLU.1 (15ug/0.5ml) for the Chinese central,government. Out of ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Organovo Appoints Robert Baltera to Board 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Proliferin (C-14)...
... submarine gel systems used gasketed gel trays. Turn the ... tank. Turn it back and run the gel - ... Turn & Cast tray is UV transparent. Each tray ... the tray and one in the center. This allows ...
Biology Products: